MacroGenics Inc
Change company Symbol lookup
Select an option...
MGNX MacroGenics Inc
NVOS Novo Integrated Sciences Inc
PAYS Paysign Inc
SELB Selecta Biosciences Inc
HLIO Helios Technologies Inc
AOUT American Outdoor Brands Inc
ZD Ziff Davis Inc
AGAC African Gold Acquisition Corp
LEA Lear Corp
PRT PermRock Royalty Trust
Go

Health Care : Biotechnology | Small Cap Value
Company profile

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Closing Price
$2.95
Day's Change
-0.07 (-2.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.07
Day's Low
2.90
Volume
(Light)
Volume:
663,431

10-day average volume:
2,909,366
663,431

Company Profile

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
2.58x
Price/Book (MRQ)
1.04x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

June 2022
Current Month
7.7M
Previous Month
6.1M
Percent of Float
13.32%
Days to Cover
6.2438 Days

Share Information

MGNX is in a share class of common stock
Float
58.2M
Shares Outstanding
61.3M
Institutions Holding Shares
205
97.20%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • William K. Heiden
  • Scott KoenigPres.
  • James KarrelsCFO
  • Eric RisserCOO
  • Ezio BonviniSr.VP

Address

Insider Trading

During the most recent quarter, 40K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.